RE: How high and why (realistic)1 May 2020 09:28
Forget the share price for initial valuations or camparisons. Look at the Market Caps. I see no reason why ODX should not attain a Market Cap of £280Million, based on NYCT, which in my view has a less vauluable suite of products and less potential. ODX have the patent for the Visitect CD4 test technology which too many doubters are totally overlooking. Also, Antibody testing will be needed before administering of a vaccine. At £280Mill Mcap the ODX share price would be in the region of £1.85. GLA dyor.